- Joined
- Feb 25, 2004
- Messages
- 893
- Reaction score
- 1
Manhattan-based Colgate-Palmolive Co. and biotech firm Introgen Therapeutics Inc. signed an agreement to develop oral care products aimed at fighting mouth cancer.
Colgate bought $20 million of Austin, Tex.-based Introgens shares and acquired the rights to any products developed by the two companies. Introgen uses gene therapy to create anti-cancer agents.
Researchers will use Introgens tumor suppressors to create oral rinses, gels and other products to treat patients diagnosed with leukoplakia -- a pre-cancerous condition that can lead to oral cancer.
http://www.medgadget.com/archives/2005/11/prevent_oral_ca_1.html
Colgate bought $20 million of Austin, Tex.-based Introgens shares and acquired the rights to any products developed by the two companies. Introgen uses gene therapy to create anti-cancer agents.
Researchers will use Introgens tumor suppressors to create oral rinses, gels and other products to treat patients diagnosed with leukoplakia -- a pre-cancerous condition that can lead to oral cancer.
http://www.medgadget.com/archives/2005/11/prevent_oral_ca_1.html